Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
暂无分享,去创建一个
G. Reifenberger | M. Weller | M. Westphal | G. Schackert | T. Pietsch | B. Hentschel | M. Sabel | J. Felsberg | F. Kreth | N. Thon | S. Eigenbrod | M. Löffler | J. Tonn
[1] B. Marples,et al. DNA mismatch repair and the DNA damage response to ionizing radiation: making sense of apparently conflicting data. , 2010, Cancer treatment reviews.
[2] H. Mehdorn,et al. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma , 2010, Neurological research.
[3] A. Brandes,et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. , 2010, Neuro-oncology.
[4] M. Wolter,et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing , 2010, Acta Neuropathologica.
[5] G. Reifenberger,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.
[6] S. Spiegl-Kreinecker,et al. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. , 2010, Neuro-oncology.
[7] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Fimmers,et al. Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.
[9] Stephen Yip,et al. MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance , 2009, Clinical Cancer Research.
[10] A. Brodbelt,et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy , 2009, British Journal of Cancer.
[11] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[12] T. Nilsson,et al. Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes. , 2009, Oncology reports.
[13] D. Rigamonti,et al. Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells. , 2009, Biochemical and biophysical research communications.
[14] H. Heinzl,et al. Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.
[15] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[16] Shinya Tanaka,et al. Careful Exclusion of Non-neoplastic Brain Components is Required for an Appropriate Evaluation of O6-methylguanine-DNA Methyltransferase Status in Glioma: Relationship Between Immunohistochemistry and Methylation Analysis , 2008, The American journal of surgical pathology.
[17] R. McLendon,et al. Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma , 2008, Clinical Cancer Research.
[18] C. James,et al. Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma , 2008, Clinical Cancer Research.
[19] M. Christmann,et al. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.
[20] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[21] Rebecca A Betensky,et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] J. Schramm,et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. , 2007, The Journal of molecular diagnostics : JMD.
[23] T. Dóczi,et al. Epigenetic Inactivation of the hMLH1 Gene in Progression of Gliomas , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[24] T. Mikkelsen,et al. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue , 2007, Laboratory Investigation.
[25] D. Chang,et al. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedside , 2007, Familial Cancer.
[26] Tracy T Batchelor,et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.
[27] P. Kleihues,et al. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.
[28] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[29] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[30] Y. Katayama,et al. Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea , 2005, Clinical Cancer Research.
[31] M. Wolter,et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors , 2005, International journal of cancer.
[32] R. Martínez,et al. Molecular Mechanisms Associated with Chromosomal and Microsatellite Instability in Sporadic Glioblastoma multiforme , 2004, Oncology.
[33] Y. Katayama,et al. Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas , 2003, Brain pathology.
[34] T. Yoshimoto,et al. Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene , 2000, Oncogene.
[35] R. McLendon,et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] S. Leung,et al. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. , 1998, The American journal of pathology.
[37] S. Keir,et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. , 1997, Cancer research.
[38] J. Bruner,et al. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. , 1997, Cancer research.
[39] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.